



Glenmark to market Tiotropium Bromide DPI in Europe

30 August 2018 | News

This is the second inhalation product in-licensed by Glenmark for the European market.

Glenmark Pharmaceuticals Europe has entered into an exclusive licensing agreement for marketing generic Tiotropium Bromide dry powder inhaler, used in the treatment of chronic obstructive pulmonary disease, in Western Europe.

According to Glenmark, respiratory is a core area of focus and this deal shows their commitment to increase product offerings within this segment.

This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler. Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim's Spiriva Handihaler.